Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
Clinical trial NCT05904093 · RECRUITING
Trial details
- NCT number
- NCT05904093
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-18
- Primary completion
- 2027-05-14
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.